Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study.

  title={Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study.},
  author={G{\"u}nter Ochs and Albrecht Struppler and B. A. Meyerson and Bengt Linderoth and Jan M. Gybels and Brian P. Gardner and P. J. Teddy and Ali Jamous and P Weinmann},
  journal={Journal of Neurology, Neurosurgery \& Psychiatry},
  pages={933 - 939}
Twenty eight patients with severe, intractable spasticity have been treated by chronic intrathecal administration of baclofen. An implantable programmable drug-administration-device (DAD) was used with a permanent intrathecal catheter. Infusion of 50 to 800 micrograms/day of baclofen completely abolished spasticity. Follow-up was up to two years. Therapeutic effect was documented by clinical assessment of tone, spasms and reflexes and by electrophysiological recordings of mono- and polysynaptic… 

A review of intrathecal baclofen in the management of spasticity.

  • B. Porter
  • Medicine
    British journal of nursing
  • 1997
The mechanism of action of baclofen, the delivery systems available and the criteria for patient selection are described, and the screening phase, surgical procedure and specific postoperative observations are described.

Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients

Despite an advanced stage of the disease at the time of pump placement, the complication rate was low, the efficacy of this treatment was maintained over time, and in almost all cases, IT baclofen was proposed to patients who were no longer able to walk.

Intrathecal baclofen for spasticity of spinal origin: seven years of experience.

  • R. Penn
  • Medicine
    Journal of neurosurgery
  • 1992
It is suggested that long-term control of spinal spasticity by intrathecal baclofen can be achieved in most patients.

Intrathecal baclofen for treatment of intractable spinal spasticity.

Intrathecal baclofen infusion: an innovative approach for controlling spinal spasticity.

  • S. SavoyJ. Gianino
  • Medicine
    Rehabilitation nursing : the official journal of the Association of Rehabilitation Nurses
  • 1993
An innovative therapy for controlling spasticity is introduced and the nurse's role in patient selection and management is discussed.

Intrathecal baclofen for treatment of spasticity.

The paper by Ochs et al' confirms the findings of Dr Penn et al 23 that chronic intrathecal administration of baclofen may be effective in relieving spasticity due to spinal cord damage and confirms that the response of intratheCal bacl ofen will vary according to the underlying pathological process.

Intrathecal baclofen in hereditary spastic paraparesis.

Intrathecal baclofen has not been previously evaluated for the treatment of the disabling hypertonia associated with hereditary spastic paraparesis. Muscle tone and deep-tendon reflexes were

Long Term Intrathecal Baclofen Therapy in Patients with Intractable Spasticity

Intrathecal baclofen therapy delivered by means of implanted infusion pumps was used for nine patients with severe spasticity who showed improvement in many areas, including ability to transfer, seating, pain control, personal care, and liability to skin breakdown.

Intrathecal Baclofen for Intractable Spinal Spasticity – a Double-blind Cross-over Comparison with Placebo in 6 Patients

In contrast to the placebo injections, the group responded to the baclofen injections with subjective and objective, clinically significant improvement in parameters of spasticity in their lower limbs, including muscle tone, frequency of spasms, hyperreflexia and passive range of joint motion.



Chronic intrathecal morphine for intractable pain.

The results of this study support earlier studies on the application of chronic intrathecal morphine for intractable cancer pain and indicate that, in carefully selected patients, nonmalignant pain may be managed satisfactorily with this technique.

Physostigmine Reversal of Baclofen-induced Sedation

Intrathecal baclofen was introduced by Penn for treatment of severe spinal spasticity [5]. In two of his so far eight patients he reported on symptoms of overdose, which possibly were due to a

Baclofen in the treatment of trigeminal neuralgia: Double‐blind study and long‐term follow‐up

Baclofen is a useful drug in the treatment of trigeminal neuralgia and an open trial in 50 patients refractory to or unable to tolerate carbamazepine showed that 37 patients were relieved of their attacks by bacl ofen.

A new agent for the control of spasticity

In a preliminary controlled trial, CIBA 34,647-Ba, a gamma aminobutyric acid derivative, was found to be more effective than placebo in reducing spasticity due to spinal injuries. In an uncontrolled

Efficacy of baclofen in trigeminal neuralgia and some other painful conditions. A clinical trial.

Results substantiate that baclofen is useful in the treatment of trigeminal neuralgia and other painful conditions.

Spinal cord stimulation for spasticity.

After the dramatic improvement of multiple sclerosis patients reported by Cook and Weinstein (1973), spinal cord stimulation (SCS) for the relief of spasticity and motor dyskinesias has been applied

Present state of extradural and intrathecal opioid analgesia in Sweden. A nationwide follow-up survey.

The results of the present nationwide survey suggests that, following extradural morphine, surveillance of patients for more than 12 h appears unnecessary.